Use of aromatase inhibitor forms basis of warning letter

By Hank Schultz contact

- Last updated on GMT

Use of aromatase inhibitor forms basis of warning letter

Related tags: Adulteration, Warning letter, Fda, muscle building, Drug

A recently posted warning letter cites a New York company for the presence of an aromatase inhibitor in one of its dietary supplements. This class of chemicals is popular with strength trainers for its purported ability to suppress estrogen levels.

Muscle builders seeking the ultimate in shredded physiques have long focused on boosting testosterone levels as one way to get there. But limiting estrogen in the system has been seen as playing a role, too, as higher levels of this hormone have been associated with higher body fat levels.

The US Food and Drug Administration inspected the facility operated by VMI Sports (Performance Nutrition Formulators, LLC) in late October 2017. FDA sent a warning letter to the company on May 18, 2018​.

In the warning letter, FDA cited a number of violations that caused the supplements packaged and shipped from the company’s facility in Hicksville, NY to be adulterated. Chief among these was the inclusion of an ingredient called Arimistane (Androsta-3,5-Diene-7,17-Dione) in a product meant to help depress estrogen levels.

“The ‘Arimistane' ingredient listed on your product label, Androsta-3,5-Diene-7,17-Dione, is an aromatase inhibitor and does not constitute a dietary ingredient under section 201(ff)(1) of the FD&C Act,”​ the agency wrote. 

FDA rules ingredient is prescription drug

FDA claimed the company was making illegal disease type claims on the product, making it in effect a drug.

The agency also took the somewhat unusual step of ruling that it is a prescription drug, “[B]ecause of its toxicity or other potentiality for harmful effect, or the method of its use, or the collateral measures necessary to its use, it is not safe for use except under the supervision of a practitioner licensed by law to administer it. Adverse events associated with the use of FDA-approved aromatase inhibitors include the following: decreased rate of bone maturation and growth, decreased sperm production, infertility, aggressive behavior, adrenal insufficiency, kidney failure, and liver dysfunction.”

Certain aromatase inhibitors have been used in breast cancer therapy​, where they can help constrain the growth of hormone-responsive tumors. The ingredient also appears on the World Anti Doping Agency’s list of banned substances​.  

Similar to legal ingredient

Androsta-3,5-Diene-7,17-Dione is chemically similar to 7-Keto DHEA, with some references listing as a metabolite. 7-Keto DHEA is legally on the market, with a successful NDI notification dating back to 1997​ that was filed jointly by GNC and Humanetics.

After developing and marketing the ingredient over the course of 14 years, in 2014 Humanetics sold it to InterHealth prior to that company’s acquisition by Lonza​.

Consumer demand plays role

Despite years of enforcement, adulterated sports supplements continue to appear in the market, and it’s an issue not confined to the US.

A recent study done on supplements in Greece found that about 10% of the supplements consumed by young, recreational athletes in that country contained anabolic steroids, prohormones, selective androgen receptor modulators (SARMs), and aromatase inhibitors

The authors of the study, which appeared in the journal Food and Chemical Toxicology​, said one reason these products continue to appear is that consumers actively seek them out.

Related news

Show more

Related products

show more

Zeal Technology™ - Liposomal powder formulations

Zeal Technology™ - Liposomal powder formulations

Aurea BioLabs | 12-Oct-2018 | Technical / White Paper

Aurea Biolabs launches Zeal Technology™ - The World's first liposomal delivery process (patent pending) for stable powder formulations that helps...

Zeal Technology™ - Liposomal powder formulations

Zeal Technology™ - Liposomal powder formulations

Aurea BioLabs | 12-Oct-2018 | Technical / White Paper

Aurea Biolabs launches Zeal Technology™ - The World's first liposomal delivery process (patent pending) for stable powder formulations that helps...

Customized Fill Release in Gelatine Soft Capsules

Customized Fill Release in Gelatine Soft Capsules

Gelita AG | 11-Oct-2018 | Technical / White Paper

From rapid release in the stomach for e.g. analgesics to enteric release for fills with unpleasant aftertaste – GELITA delivers the respective gelatine...

Breakfast with the Experts at Supply Side West

Breakfast with the Experts at Supply Side West

KGK Science, Inc. | 08-Oct-2018 | Event Programme

For natural health products statistical significance may not be as important as clinical relevance in healthy populations. With a shifting focus towards...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars